Robert Shepard Email

CMO - Part-time . Moleculin Biotech

Current Roles

Employees:
27
Revenue:
$5.4M
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical-stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer, and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.
Moleculin Biotech Address
5300 Memorial Drive
Houston, TX
United States
Moleculin Biotech Email

Past Companies

Hematology/Oncology Drug Development and Clinical Trials ConsultingPrincipal Consultant
Moleculin, LLCCMO - Part-time
Dr. Robert ShepardConsultant in oncology clinical trials and drug development

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.